The diagnostic sensitivity (SN), specificity (SP), positive likely-hood ratio (LR+), and negative likely-hood ratio (LR–) of all three core CSF biomarkers (Aβ42: SN = 79%, SP = 63%, LR+ = 2, and LR– = 0.3; tau: SN = 76%, SP = 58%, LR+ = 2, and LR– = 0.4; p-tau: SN = 78%, SP = 56%, LR+ = 2, and LR– = 0.4; combination of three: Aβ42: SN = 84%, SP = 63%, LR+ = 2, and LR– = 0.3) for MCI conversion to AD were found to be moderate by a systemic meta-analysis (Ferreira et al., 2014). The gene discussed is MAPT; the disease is Alzheimer disease.